Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group study N0074 ()

BACKGROUND/RATIONALE: Amplification of the epidermal growth factor receptor (EGFR) gene represents one of the most frequent gene alterations in glioblastoma (GBM). In the current study, we evaluated gefitinib, a potent EGFR inhibitor, in the treatment of adults with newly diagnosed GBM. METHODS: 98...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Radiat Oncol Biol Phys
Hlavní autoři: Uhm, Joon H., Ballman, Karla V., Wu, Wenting, Giannini, Caterina, Krauss, JC, Buckner, Jan C., James, C.D, Scheithauer, Bernd W., Behrens, Robert J., Flynn, Patrick J., Schaefer, Paul L., Dakhill, Shaker R., Jaeckle, Kurt A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2010
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5753591/
https://ncbi.nlm.nih.gov/pubmed/20510539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijrobp.2010.01.070
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky